Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Standard BioTools Inc.’s mass cytometry systems shape immunotherapy studies worldwide, even a single line in the 10-K can move markets. Investors often ask, “Where can I review Standard BioTools quarterly earnings report 10-Q filing?” or “How do I track Standard BioTools insider trading Form 4 transactions?” Those answers live inside dense SEC documents—finding them can drain hours.
Stock Titan turns that complexity into clarity. Our AI delivers Standard BioTools SEC filings explained simply, spotlighting revenue from proteomics instruments, R&D cash burn, and obligations tied to leased manufacturing sites. You’ll see each Standard BioTools annual report 10-K simplified and Standard BioTools 8-K material events explained within minutes of hitting EDGAR. Real-time alerts surface Standard BioTools Form 4 insider transactions real-time, ensuring you never miss meaningful Standard BioTools executive stock transactions Form 4. Need faster context? Every Standard BioTools earnings report filing analysis pairs key metrics with peer benchmarks for immediate comparison.
Whether you’re building a valuation model or evaluating management incentives, critical disclosures are one click away:
- Track Standard BioTools proxy statement executive compensation to understand leadership alignment
- Compare margins and backlog across each Standard BioTools quarterly earnings report 10-Q filing
- Receive alerts on emerging risks via Standard BioTools 8-K material events explained
Understanding Standard BioTools SEC documents with AI means spending less time scrolling and more time deciding. Every filing, every footnote—decoded and delivered in real time.
Casdin-related entities and Eli Casdin reported a purchase of 100,000 shares of Standard BioTools, Inc. common stock at a weighted-average price of $1.2892 per share on 09/09/2025. The filing shows the shares were acquired in multiple transactions within a narrow price range and that the reporting persons hold large indirect positions: the Master Fund is shown as directly owning securities and several affiliated funds and entities are listed as indirect owners, with a reported total of 60,875,000 shares beneficially owned by the Master Fund reporting group after the transaction. The report also discloses direct ownership by Eli Casdin and by two Casdin private growth funds, and notes deputization of Mr. Casdin to represent the reporting persons on the company board.
Casdin-related entities reported multiple transactions in Standard BioTools, Inc. (LAB). On 09/03/2025 and 09/04/2025, Casdin Partners Master Fund, L.P. purchased 250,000 shares each day at weighted-average prices of $1.2656 and $1.2774, respectively, increasing beneficial holdings to 60,525,000 and 60,775,000 shares as reported. Eli Casdin directly disposed of 2,901,062 shares. The filing lists additional direct holdings: Casdin Private Growth Equity Fund II, L.P. holds 13,939,637 shares and Casdin Private Growth Equity Fund, L.P. holds 2,744,219 shares. Footnotes explain weighted-average price ranges and indirect ownership through adviser and general partner relationships. The reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Form 4 filings from multiple Casdin entities report insider purchases and a single disposition in Standard BioTools, Inc. (LAB). The Master Fund purchased 200,000 shares on 08/22/2025 at $1.2634 and 200,000 shares on 08/25/2025 at a weighted-average price reported as $1.2409 (range $1.2311–$1.2475). On 08/26/2025 the Master Fund bought 125,000 shares at $1.2635. Following these buys the Reporting Persons report beneficial ownership totals rising to as much as 60,275,000 shares (indirect). Separately, Eli Casdin directly disposed of 2,901,062 shares. Various Casdin funds and management entities are listed as reporting persons and Mr. Casdin is deputized to represent them on the issuer's board.
Michael Egholm, President & CEO and Director of Standard BioTools Inc. (LAB), reported a transaction dated 08/20/2025 in which 54,919 shares of common stock were disposed (Transaction Code F) at $1.27 per share. The filing states these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on May 20, 2024 and March 21, 2025, previously reported on Form 4s. After the withholding, the reporting person beneficially owns 5,681,366 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Egholm.
Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc. (LAB), reported a disposition of 19,661 shares of common stock on 08/20/2025. The filing shows the sale was coded F and executed at $1.27 per share. The report explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units originally granted on May 20, 2024 and March 21, 2025.
After the withholding, Mackay beneficially owns 799,496 shares, held directly. The transaction is a routine withholding to cover taxes tied to equity compensation rather than an open-market sale for other purposes.
Standard BioTools (LAB) Chief Financial Officer Hanjoon Alex Kim reported a disposition of 12,739 shares of common stock on 08/20/2025 at a price of $1.27 per share. The Form 4 shows the shares were withheld to satisfy tax withholding obligations arising from restricted stock units that vested from grants made on May 20, 2024 and March 21, 2025. After the reported disposition, the reporting person beneficially owns 2,427,825 shares. The filing was signed by an attorney-in-fact on behalf of Mr. Kim on 08/22/2025.
Casdin-affiliated entities reported multiple open-market purchases of Standard BioTools Inc. (LAB) common stock between 08/13/2025 and 08/15/2025. The filings show aggregated acquisitions of at least 358,220 shares at weighted-average prices of approximately $1.21–$1.31, resulting in total beneficial ownership of 59,750,000 shares (held indirectly by the reporting entities) and certain direct holdings by Eli Casdin. The report also discloses a 2,901,062-share disposition directly by Eli Casdin and additional direct holdings of 13,939,637 and 2,744,219 shares by two Casdin funds. Eli Casdin is deputized to represent the reporting persons on LAB's board.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
